These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7692922)

  • 1. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
    Dercksen MW; Hoekman K; ten Bokkel Huinink WW; Rankin EM; Dubbelman R; van Tinteren H; Wagstaff J; Pinedo HM
    Br J Cancer; 1993 Nov; 68(5):996-1003. PubMed ID: 7692922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
    Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
    J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
    Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
    Postmus PE; Gietema JA; Damsma O; Biesma B; Limburg PC; Vellenga E; de Vries EG
    J Clin Oncol; 1992 Jul; 10(7):1131-40. PubMed ID: 1318953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer.
    Biesma B; van Kralingen KW; van Leen RW; Koster MC; Postmus PE
    J Exp Ther Oncol; 2002; 2(1):47-52. PubMed ID: 12415620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.
    Biesma B; Willemse PH; Mulder NH; Sleijfer DT; Gietema JA; Mull R; Limburg PC; Bouma J; Vellenga E; de Vries EG
    Blood; 1992 Sep; 80(5):1141-8. PubMed ID: 1515636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical study on the effects of recombinant human interleukin-3 on thrombocytopenia after chemotherapy for advanced ovarian cancer. SDZ ILE 964 [IL-3] Study Group.
    Yamamoto K; Yajima A; Terashima Y; Nozawa S; Taketani Y; Yakushiji M; Noda K
    J Immunother; 1999 Nov; 22(6):539-45. PubMed ID: 10570752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
    Meden H; Fock M; Krauss T; Kuhn W
    Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.
    Veldhuis GJ; Willemse PH; Sleijfer DT; van der Graaf WT; Groen HJ; Limburg PC; Mulder NH; de Vries EG
    J Clin Oncol; 1995 Oct; 13(10):2585-93. PubMed ID: 7595711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
    Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
    Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
    D'Hondt V; Weynants P; Humblet Y; Guillaume T; Canon JL; Beauduin M; Duprez P; Longueville J; Müll R; Chatelain C
    J Clin Oncol; 1993 Nov; 11(11):2063-71. PubMed ID: 8229120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent stimulation of thrombopoesis with interleukin-3 (IL-3) in chemotherapy induced myelosuppression.
    Schweiger C; Färber L; Füchsel G; Heinrich D; Meinerz W
    Biofactors; 1995-1996; 5(2):73-4. PubMed ID: 8722119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
    Speyer JL; Mandeli J; Hochster H; Runowicz C; Wadler S; Wallach R; Cohen C; Oette D; Sorich J; Demakos E
    Gynecol Oncol; 1995 Mar; 56(3):387-94. PubMed ID: 7705673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.
    Rinehart J; Hersh E; Issell B; Triozzi P; Buhles W; Neidhart J
    Cancer Invest; 1997; 15(5):403-10. PubMed ID: 9316621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.
    Tepler I; Elias A; Kalish L; Shulman L; Strauss G; Skarin A; Lynch T; Levitt D; Resta D; Demetri G
    Br J Haematol; 1994 Aug; 87(4):678-86. PubMed ID: 7986706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells.
    Saitoh M; Taguchi K; Momose K; Suga K; Yamazaki N; Ono C; Suzuki T; Takeuchi O; Yasuda S; Miyata K
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):161-6. PubMed ID: 11862431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3--a report on four cases.
    Färber L; Haus U; Füchsel G; Theml H; Chatsiproios D; Schmid H; Burger KJ; Drechsler S
    Anticancer Drugs; 1997 Mar; 8(3):288-92. PubMed ID: 9095335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.